In the following subsection, we therefore turn to breast cancer, where HER2 amplification and dysregulation of the PI3K-AKT-mTOR pathway have led to similarly transformative yet still incomplete advances in molecular-targeted therapy. The gene discussed is ERBB2; the disease is breast carcinoma.